AMGN congressional trades
Amgen Inc. (AMGN) appears in 35 congressional disclosure rows from 16 members of Congress in 2025–2026 periodic reports: 17 purchases and 18 sales, with trade dates from Aug 7, 2024 to Sep 22, 2026. David Taylor reported the most, with 9 rows. The median gap between trade date and filing date is 23 days, and 7 trades were reported more than 45 days after it happened.
Rows keep the disclosed owner and amount range. This is a record of reported transactions, not a live AMGN portfolio or a trading signal.
- 35
- 16
- 17 / 18
- $147K – $805K
- sum of reported ranges
- 2026-09-22
Verified AMGN congressional disclosures
Parsed from official House Clerk and Senate eFD filings. This snapshot contains 17 purchases and 18 sales. Reported owners: Self, Spouse, Dependent, Joint. Transaction dates run from 2024-08-07 to 2026-09-22.
| Politician | Trade date | Asset | Type | Owner | Amount | Filing |
|---|---|---|---|---|---|---|
| David Taylor | Amgen Inc. - Common Stock | Purchase | Self | $1,001 - $15,000 | #20035549 Filed 2026-10-01 | |
| David Taylor | Amgen Inc. - Common Stock | Sale | Self | $1,001 - $15,000 | #20035392 Filed 2026-09-05 | |
| David Taylor | Amgen Inc. - Common Stock | Sale | Self | $1,001 - $15,000 | #20035392 Filed 2026-09-05 | |
| Sheldon Whitehouse | Amgen Inc. - Common Stock | Sale | Spouse | $1,001 - $15,000 | #f8d003c0-ca1e-4c39-9d66-632d220180e1 Filed 2026-09-02 | |
| David Taylor | Amgen Inc. - Common Stock | Purchase | Self | $1,001 - $15,000 | #20034780 Filed 2026-06-12 | |
| Maria Salazar | Amgen Inc. - Common Stock | Sale | Self | $15,001 - $50,000 | #20034479 Filed 2026-05-08 | |
| Alan Armstrong | Amgen Inc. - Common Stock | Sale | Self | $15,001 - $50,000 | #fda235b3-bad7-4637-8fa1-053f354d929c Filed 2026-07-21 | |
| Maria Salazar | Amgen Inc. - Common Stock | Purchase | Self | $15,001 - $50,000 | #20033993 Filed 2026-04-21 | |
| David Taylor | Amgen Inc. - Common Stock | Sale | Self | $1,001 - $15,000 | #20034138 Filed 2026-03-06 | |
| David Taylor | Amgen Inc. - Common Stock | Sale | Self | $1,001 - $15,000 | #20033916 Filed 2026-02-02 | |
| David Taylor | Amgen Inc. - Common Stock | Purchase | Self | $1,001 - $15,000 | #20033916 Filed 2026-02-02 | |
| David Taylor | Amgen Inc. - Common Stock | Sale | Self | $1,001 - $15,000 | #20033590 Filed 2025-12-05 | |
| David Taylor | Amgen Inc. - Common Stock | Sale | Self | $1,001 - $15,000 | #20033590 Filed 2025-12-05 | |
| Marjorie Greene | Amgen Inc. - Common Stock | Purchase | Self | $1,001 - $15,000 | #20033360 Filed 2025-10-28 | |
| Lisa McClain | Amgen Inc. - Common Stock | Sale | Spouse | $1,001 - $15,000 | #20032129 Filed 2025-10-22 | |
| Marjorie Greene | Amgen Inc. - Common Stock | Purchase | Self | $1,001 - $15,000 | #20032174 Filed 2025-09-27 | |
| Sheldon Whitehouse | Amgen Inc | Sale | Self | $1,001 - $15,000 | #12bfb6c8-5dbf-4f2a-994b-c936a0a0a91d Filed 2025-10-03 | |
| Lisa McClain | Amgen Inc. - Common Stock | Purchase | Spouse | $1,001 - $15,000 | #20030891 Filed 2025-08-13 | |
| Cliff Bentz | Amgen Inc. - Common Stock | Purchase | Spouse | $1,001 - $15,000 | #20030646 Filed 2025-07-09 | |
| Marjorie Greene | Amgen Inc. - Common Stock | Purchase | Self | $1,001 - $15,000 | #20030389 Filed 2025-05-19 | |
| Jefferson Shreve | Amgen Inc. - Common Stock | Sale | Self | $15,001 - $50,000 | #20030387 Filed 2025-06-22 | |
| Marjorie Greene | Amgen Inc. - Common Stock | Purchase | Self | $1,001 - $15,000 | #20030295 Filed 2025-05-06 | |
| Jared Moskowitz | Amgen Inc. - Common Stock | Purchase | Dependent | $1,001 - $15,000 | #20030282 Filed 2025-05-09 | |
| Jared Moskowitz | Amgen Inc. - Common Stock | Purchase | Self | $1,001 - $15,000 | #20030282 Filed 2025-05-09 | |
| Tommy Tuberville | Amgen Inc | Sale | Joint | $15,001 - $50,000 | #014817f0-9809-457f-8ac5-048948608e02 Filed 2026-08-05 | |
| Tommy Tuberville | Amgen Inc | Sale | Joint | $15,001 - $50,000 | #63e4a2b1-5bfc-43b6-b952-ba54e377212c Filed 2025-05-15 | |
| Jefferson Shreve | Amgen Inc. - Common Stock | Purchase | Self | $15,001 - $50,000 | #20030231 Filed 2025-05-08 | |
| Robert Bresnahan | Amgen Inc. - Common Stock | Sale | Self | $1,001 - $15,000 | #20030291 Filed 2025-05-08 | |
| Jefferson Shreve | Amgen Inc. - Common Stock | Purchase | Self | $15,001 - $50,000 | #20027879 Filed 2025-03-09 | |
| Daniel Meuser | Amgen Inc. - Common Stock | Sale | Spouse | $1,001 - $15,000 | #20030922 Filed 2025-08-20 | |
| Emily Randall | Amgen Inc. - Common Stock | Sale | Spouse | $1,001 - $15,000 | #20026756 Filed 2025-02-11 | |
| Virginia Foxx | Amgen Inc. - Common Stock | Purchase | Self | $1,001 - $15,000 | #20026516 Filed 2025-01-06 | |
| Julia Letlow | Amgen Inc. - Common Stock | Sale | Self | $1,001 - $15,000 | #20030977 Filed 2026-01-13 | |
| Julia Letlow | Amgen Inc. - Common Stock | Purchase | Self | $1,001 - $15,000 | #20030977 Filed 2026-01-13 | |
| C. Franklin | Amgen Inc. - Common Stock | Purchase | Spouse | $1,001 - $15,000 | #20030494 Filed 2025-07-03 |
A filing can describe the member, a spouse, a dependent, or a joint asset. Amounts are statutory ranges, not execution prices. See how to read congressional stock-trade disclosures before treating a delayed row as a trading signal.
AMGN disclosures by member
| Member | Rows | Buys | Sells | Last trade |
|---|---|---|---|---|
| David Taylor's AMGN trades | 9 | 3 | 6 | 2026-09-22 |
| Marjorie Greene's AMGN trades | 4 | 4 | 0 | 2025-10-24 |
| Jefferson Shreve's AMGN trades | 3 | 2 | 1 | 2025-05-12 |
| Jared Moskowitz | 2 | 2 | 0 | 2025-04-16 |
| Julia Letlow | 2 | 1 | 1 | 2024-11-19 |
| Lisa McClain | 2 | 1 | 1 | 2025-09-25 |
| Maria Salazar | 2 | 1 | 1 | 2026-04-17 |
| Sheldon Whitehouse | 2 | 0 | 2 | 2026-08-12 |
| Tommy Tuberville | 2 | 0 | 2 | 2025-04-15 |
| Alan Armstrong | 1 | 0 | 1 | 2026-03-27 |
| C. Franklin | 1 | 1 | 0 | 2024-08-07 |
| Cliff Bentz | 1 | 1 | 0 | 2025-06-06 |
| Daniel Meuser | 1 | 0 | 1 | 2025-02-11 |
| Emily Randall | 1 | 0 | 1 | 2025-01-06 |
| Robert Bresnahan | 1 | 0 | 1 | 2025-04-08 |
| Virginia Foxx | 1 | 1 | 0 | 2024-12-06 |
How long disclosure took
Days from trade date to filing date for 35 rows. The STOCK Act allows 30 days from notification and no more than 45 days from the trade. A late row is a timing fact, not evidence of wrongdoing.
- 0–15 days
- 12
- 16–30 days
- 12
- 31–45 days
- 4
- Over 45 days
- 7
- Median / longest
- 23d / 477d
Source documents
30 House Clerk and Senate eFD periodic transaction reports, newest first. Each link opens the official filing.
- #20035549Filed 2026-10-01 · 1 row
- #20035392Filed 2026-09-05 · 2 rows
- #f8d003c0-ca1e-4c39-9d66-632d220180e1Filed 2026-09-02 · 1 row
- #014817f0-9809-457f-8ac5-048948608e02Filed 2026-08-05 · 1 row
- #fda235b3-bad7-4637-8fa1-053f354d929cFiled 2026-07-21 · 1 row
- #20034780Filed 2026-06-12 · 1 row
- #20034479Filed 2026-05-08 · 1 row
- #20033993Filed 2026-04-21 · 1 row
- #20034138Filed 2026-03-06 · 1 row
- #20033916Filed 2026-02-02 · 2 rows
- #20030977Filed 2026-01-13 · 2 rows
- #20033590Filed 2025-12-05 · 2 rows
18 older filings are linked from the transaction table.
What AMGN filings don’t tell you
A disclosure row records a trade date, an amount bracket, and who owned the asset. It does not say why the trade was made, whether the position is still held, or anything about the business behind the ticker: revenue trends, margins, balance-sheet risk, or valuation. Those answers are in company filings, not congressional ones.
- Amgen Inc. financials and filings
Audited SEC figures, what moves AMGN, and primary sources.
To work through a company yourself, use our stock research checklist. Members get the full version of that work: one sourced investment call a month, with the numbers and the risks that would change the view.
Members-only research
What members are reading this month
- NVIDIA’s growth has a financing bill
Sales up about 18% on the prior quarter, receivables up about 55%, supply commitments at $279 billion. What NVIDIA’s financing bill means for the price you pay.
- Citadel bought the AI fire sale. The seller had run out of time.
Up 439% in the first half, down about 67% in July: how an AI hedge fund ended up selling a roughly $16 billion stock book to Citadel at a discount.
The thesis, the numbers behind it, and what would break it. Full access is $39 a month.
Read the full researchRelated research
AMGN congressional trades: FAQ
Who in Congress traded AMGN?
House Clerk and Senate eFD periodic reports for 2025 and 2026 contain 35 verified AMGN rows from 16 members: Alan Armstrong, C. Franklin, Cliff Bentz, Daniel Meuser, and 12 other members. Image-only filings are excluded, and this is not a live brokerage statement.
Does this page show current AMGN holdings?
No. STOCK Act filings disclose reportable transactions after the fact, usually within 45 days, as amount ranges and owners. They do not prove a current position, an exact share count, or why the trade happened.
Why are AMGN amounts shown as ranges?
Congressional periodic transaction reports use statutory value bands such as $1,001 - $15,000; $15,001 - $50,000. Yield Theory keeps those ranges instead of inventing a midpoint, exact trade size, or return.
How complete is AMGN congressional-trade coverage?
This snapshot covers every machine-readable House and Senate periodic transaction report for 2025 and 2026 (177 members). Image-only House filings and paper Senate filings are not included, so missing rows are not proof that no other lawmaker traded AMGN.
Yield Theory is not affiliated with any elected official. This page uses the 2025–2026 House Clerk and Senate eFD periodic report snapshot generated 2026-10-15. It is not a complete lifetime portfolio, a performance track record, or investment advice.
A disclosure is not a thesis.
This page shows who reported AMGN and in what range. Membership is the monthly sourced call, plus a five-minute check when the evidence moves. $39/month or $249/year.
Members-only research
$39/mo or $249/yr · cancel future renewals anytime · sources included